ulterine diseases
Conditions
Interventions
Group 1:nalbuphine 0.15mg/kg
Group 2:nalbuphine 0.2mg/kg
Group 3:sufentanil 0.15ug/kg
Sponsors
Women's Hospital School of Medicine Zhejiang University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Patients scheduled for operative hysteroscopy under monitored anaesthesia care ,ASA grade 1-2, aged 20-40 years, BMI 18-24kg/m2
Exclusion criteria
Exclusion criteria: History of spontaneous vaginal delivery; abnormal of liver and kidney function; history of cardiopulmonary disease; sleep apnea syndrome; long-term use of diazepam; long-term use of opioids; nalbuphine allergy; electrolyte disorder, infection, immune and endocrine system diseases, recent use of cardiovascular drugs, non-steroidal anti-inflammatory drugs, hormone drugs and anti-psychotic drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the target effect-site concentration of propofol (Ceprop) required to attenuate the response to cervical dilation in 50% of patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemodynamic indicators;Wake-up time;VAS rating;nausea and vomiting;Complications of the mental system; | — |
Countries
China
Contacts
Public ContactLili Xu
Women's Hospital School of Medicine Zhejiang University
Outcome results
None listed